New OBSCORE tool predicts risk of 18 obesity-related complications to guide GLP-1 therapy

A new predictive model called OBSCORE has been introduced to identify individuals at risk for a range of obesity‑related health problems. The tool expands on the traditional body‑mass index metric by incorporating additional data such as family history, dietary habits, current illnesses, and socioeconomic information drawn from medical records.

The model evaluates the likelihood of 18 serious complications linked to obesity, aiming to pinpoint patients who could benefit most from GLP‑1 medications. These drugs, originally developed for type 2 diabetes, have shown effectiveness in reducing cardiovascular disease, kidney disease, liver disease, sleep apnea, and osteoarthritis, while also promoting weight loss.

By providing a more nuanced risk assessment, OBSCORE seeks to improve the selection process for costly, lifelong GLP‑1 therapy, which has typically been based on BMI alone or in combination with a single comorbidity.

Researchers hope the integrated approach will help clinicians target treatment more precisely, potentially enhancing outcomes and optimizing resource use in obesity management.